Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: November 13, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 1946 miles
IU Simon Cancer Center
Indianapolis,IN

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03343613

LY3381916 Alone or With LY3300054 in Metastatic Breast Cancer

A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors Scientific Title

Purpose
To evaluate the safety, best dose, and effects (good and bad) of LY3381916 when it is given alone or with LY3300054.
Who is this for?
Group 1: Women and men with metastatic (stage IV) breast cancer; Group 2: Women and men with metastatic triple negative (ER-, PR- and HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3381916, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3381916, by mouth</li> <li class="seamTextUnorderedListItem">LY3300054, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy LY3381916 gets immune cells to go after cancer cells by targeting the enzyme IDO-1. </li> <li class="seamTextUnorderedListItem">The immunotherapy LY3300054 is a PD-L1 checkpoint inhibitor. It blocks a protein called PD-L1 that stops the immune system from attacking the cancer cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer. Both of these immunotherapies are investigational drugs.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03343613' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/794987' target='_blank'>NCI Drug Dictionary: IDO-1 inhibitor LY3381916</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/78/13_Supplement/CT018' target='_blank'>Cancer Research: Safety and clinical activity of a novel anti-PD-L1 antibody (LY3300054)</a> </li></ul>
See more